• In the past few days, Intellia Therapeutics reported Q2 2026 results showing a net loss of US$106.63 million, or US$0.80 per share, alongside positive Phase III data for its hereditary angioedema gene-editing therapy lonvo-z and a resumed Phase III program in transthyretin amyloidosis after clinical holds were resolved.
• These updates both highlight the financial strain of Intellia’s R&D-heavy model and mark important clinical milestones that could reshape its future commercialization path in in vivo CRISPR gene editing.
• Next, we’ll examine how the Phase III success of lonvo-z and rolling BLA plans may influence Intellia’s existing investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Intellia Therapeutics Investment Narrative Recap

To own Intellia, you need to believe in one time CRISPR treatments turning late stage programs like lonvo z and nex z into meaningful commercial franchises despite ongoing losses. Right now, the key catalyst is lonvo z’s regulatory path, while the biggest risk is execution and safety across a very concentrated pipeline. The latest results and clinical updates support lonvo z’s momentum but do not remove the broader funding and competition risks facing the business.

The most relevant update here is Intellia’s Q2 2026 earnings, which show a US$106.63 million quarterly net loss alongside a narrowed per share loss of US$0.80 and a cash balance of US$628.4 million. This financial position, combined with a runway guided into at least 2028, matters for how investors weigh lonvo z’s Phase III success and rolling BLA plans against the cash burn required to advance nex z and other programs.

Yet, while the lonvo z data look encouraging, investors should still be aware of the unresolved safety and adoption questions around one time CRISPR therapies that could...

Intellia Therapeutics' narrative projects $909.0 million revenue and $77.6 million earnings by 2029. This requires 139.6% yearly revenue growth and about a $472 million earnings increase from -$394.6 million today.

Uncover how Intellia Therapeutics' forecasts yield a $26.63 fair value, a 137% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling revenue of about US$6.0 billion and earnings near US$1.9 billion by 2029, which is far more bullish than the baseline view and could be reconsidered in light of both the lonvo z Phase III win and the lingering safety scrutiny around one time genome editing.

Explore 3 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.